Aims/hypothesis. The neurotransmitters glutamate and g-aminobutyric acid (GABA) could participate in the regulation of the endocrine functions of islets of Langerhans. We investigated the role of the metabotropic glutamate (mGluRs) and GABA B (GA-BA B Rs) receptors in this process. Methods. We studied the expression of mGluRs and GABA B Rs in rat and human islets of Langerhans and in pancreatic a-cell and beta-cell lines using RT-PCR and immunoblot analysis. Effects of mGluR and GABA B R agonists on insulin secretion were determined by radioimmunoassays and enzyme-linked immunoadsorbent assays (ELISAs). Results. We detected mGluR3 and mGluR5 (but not mGluR1, 6 and 7) mRNAs in all of the samples examined. Trace amount of mGluR2 was found in MIN6 beta cells; mGluR4 was identified in rat islets; and mGluR8 expression was detected in rat islets, RINm5F and MIN6 cells. GABA B R1 a/b and 2 mRNAs were identified in islets of Langerhans and MIN6 cells. The expression of mGluR3, mGluR5, GABA B R1 a/b and GABA B R2 proteins was confirmed using specific antibodies. Group I (mGluR1/5) and group II (mGluR2/3) specific mGluR agonists increased the release of insulin in the presence of 3 to 10 mmol/l or 3 to 25 mmol/l glucose, respectively, whereas a group III (mGluR4/ 6±8) specific agonist inhibited insulin release at high (10±25 mmol/l) glucose concentrations. Baclofen, a GABA B R agonist, also inhibited the release of insulin but only in the presence of 25 mmol/l glucose. Conclusion/interpretation. These data suggest that mGluRs and GABA B Rs play a role in the regulation of the endocrine pancreas with mechanisms probably involving direct activation or inhibition of voltage dependent Ca 2+ -channels, cAMP generation and Gprotein-mediated modulation of K ATP channels. [Diabetologia (2002) 45: 242±252] 
Pancreatic islet cells share some common features with neurones including the expression of proteins specialized for synaptic transmission and the sensitivity of islet-cell hormone secretion to neurotransmitters [1] . Glutamate and g-aminobutyric acid (GABA) are the major excitatory and inhibitory neurotransmitters in the central nervous system (CNS). These neurotransmitters are also present in islets of Langerhans and can be shown to alter hormone secretion [1±7] but their precise physiological roles in islet function and their cellular mechanisms of action are not clear. It is possible that GABA and glutamate mediate a paracrine-signalling pathway whereby a and beta cells communicate within the islets [1, 3, 6, 7] .
In neurones, the transmitter actions of glutamate are mediated by different types of receptors categorised as ionotropic (iGluR) and metabotropic (mGluR) [8, 9] . The iGluRs are multimeric, cationspecific ion channels that are classified into three families on the basis of their pharmacology, electrophysiology and sequence homology; namely the aamino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), kainate, and N-methyl-d-aspartate (NMDA) receptors [8] . Within an iGluR subclass, the subunit composition strongly influences the pharmacological and biophysical properties of the receptors [8] . The mGluRs are G-protein coupled receptors and they mediate relatively slow responses to glutamate [9] . To date, the family of mGluRs comprises eight different subtypes (mGluR1±8) classified into three groups on the basis of sequence similarities, pharmacological properties and intracellular signal transduction mechanisms [9, 10] . In group I, the mGluR1 and mGluR5 are coupled to inositol (1, 4, 5) tris phosphate (IP3)/Ca 2+ and are activated by (S)-3,5-dihydroxyphenylglycine (DHPG). In group II, the mGluR2 and mGluR3 are typically linked to inhibition of cAMP formation and react effectively with (2S, 1'S, 2'S)-2-(carboxycyclopropyl)glycine (L-CCG-1) [9, 10] . However, there are examples of group II mGluR agonists that can also potentiate cAMP responses in some cells [9, 11] . In group III, the mGluR4, mGluR6, mGluR7 and mGluR8 are linked to inhibition of cAMP formation and respond effectively to L-2-amino-4-phosphonobutyrate (L-AP4) [9, 10] . Until now the expression of mGluRs has not been identified in pancreatic islet cells, but the presence of iGluRs is well documented [12±20] . However, the precise physiological role of these iGluRs is not clear [1, 6, 7] .
In the CNS, GABA acts at two distinct types of receptors, ligand-gated ionotropic GABA A (GA-BA A Rs)and GABA C receptors, and G protein-linked metabotropic GABA B receptors (GABA B Rs), thus mediating both fast and slow inhibition of excitability at central synapses [21, 22] . To date, two major GA-BA B R isoforms (GABA B R1 and GABA B R2) and various splice variants have been described [23±29] . In CNS neurones GABA B R1 and GABA B R2 are widely co-expressed and, a novelty for heptahelical receptors, were found to generate fully functional receptors only when linked by their C-terminal tails in a heterodimeric assembly [22, 24±26] . In short-term signalling, pre-synaptically located GABA B Rs suppress neurotransmitter release by inhibiting voltagesensitive P, N, and L-type Ca 2+ channels [30] . Postsynaptically, GABA B R-stimulation generally causes inhibition of adenylyl cyclase through G ai subunits, as well as activation of Kir3 type potassium channels by liberated G bg subunits, thereby hyperpolarizing the post-synaptic membrane [23, 31] . GABA B Rs are also capable of directly interacting with transcription factors and could thus use a mechanism for gene transcription regulation upon stimulation [32±34]. In islets of Langerhans, GABA is released from beta cells and inhibits the release of glucagon from a cells [2±4]. This inhibition is believed to be mediated through GABA A Rs [1, 3, 4] . However, it has been suggested that GABA B Rs could be in the endocrine pancreas [35] , but this has not been closely examined.
In this study our aims were to determine whether mGluR and GABA B R mediated signalling mechanisms exist in islets of Langerhans and to investigate the contribution of these receptors to the modulation of glucose-stimulated insulin secretion. We investigated which of the mGluR and GABA B R isoforms are present in rat and human islets of Langerhans and pancreatic a-cell and beta-cell lines using reverse transcription polymerase chain reaction (RT-PCR) and immunochemical detection of the corresponding proteins. Furthermore, we examined and showed the functional roles of these newly identified receptors in insulin secretion.
Materials and methods
Materials. Male Wistar rats (200±250 g) were from Harlan UK (Bicester, UK). TRI-Reagent and all tissue culture materials were obtained from Sigma (Poole, Dorset, UK). DNA oligonucleotide primers were purchased from Cruachem (Glasgow, Scotland). Restriction endonucleases were from Roche Diagnostics (Lewes, UK). The mGluR and GABA B R agonists and antagonists were obtained from Tocris Cookson (Bristol, UK). All other chemicals were of analytical grade.
Isolation of islets of Langerhans and rat brain membranes. Rat islets of Langerhans were obtained by collagenase digestion of the pancreas [36] . The isolated islets were washed four times in HEPES-Krebs buffer (pH 7.4) containing 2.54 mmol/l CaCl 2 , 1.20 mmol/l MgSO 4 , 4.75 mmol/l KCl, 1.18 mmol/l K 2 HPO 4 , 119 mmol/l NaCl, 5 mmol/l NaH 2 PO 4 , 3 mmol/l dglucose, 20 mmol/l HEPES, 0.5 % (weight/volume; w/v) BSA and selected under a dissecting microscope. Human islets of Langerhans (HIL) were supplied by Dr. R. James, Department of Surgery, University of Leicester, UK and isolated [37] . For RNA preparation, all solutions were prepared using diethyl pyrocarbonate-(DEPC)-treated water. The preparation of membrane fractions from whole brain or dissected cerebellum was carried out as previously described [38] .
Cell culture. MIN6 (MIN) and RINm5F (RIN) pancreatic beta cells and a-TC pancreatic a-cells (a-TC) were maintained in DMEM tissue-culture medium containing fetal calf serum (10 % v/v), penicillin (100 units/ml) and streptomycin (0.1 mg/ ml) at 37 C in an atmosphere of humidified air (95 %) and CO 2 (5 %) [39] . Cells were passaged weekly and harvested using trypsin-EDTA. They were cultured for 3±5 days before RNA or membrane preparation.
RNA preparation, reverse transcription and PCR. Total RNA was extracted from rat and human islets of Langerhans, rat cerebral cortex (RB), cerebellum (CER), and pancreatic a and beta-cell lines using TRI-Reagent according to the manufacturer's protocol and the final RNA pellet was dissolved in DEPC-treated water. The total RNA (10 mg) was reverse-transcribed at 42 C for 60 min in 50 ml of reaction mixture containing 1 x reverse transcripts buffer (40 mmol/l KCl, 1 mmol/l dithiothreitol (DTT), 6 mmol/l MgCl 2 and 50 mmol/l Tris-HCl; pH 8.3), 200 pmol of random primers, 0.5 mmol/l of each dNTP, 10 mmol/l dithiothreitol, 40 units of rRNasin and 500 units of M-MLV reverse transcriptase (Gibco BRL, Uxbridge, Middlesex, UK). One tenth of the cDNA was subjected to a PCR in 50 ml reaction mixture containing 1 x PCR buffer (50 mmol/l KCl, 5 mmol/l dithiothreitol and 10 mmol/l TrisHCl; pH 9.0), 1.5±3 mmol/l MgCl 2 , 0.1 mmol/l of each dNTP, 40 pmol of each primer and 1 unit of Amplitaq Gold Polymerase (Perkin Elmer, Norwalk, CT, USA). PCR was carried out at 95 C for 10 min, followed by 35 cycles at 95 C for 1 min, at the appropriate annealing temperature for 1 min (Table 1) and 72 C for 1 min. The last cycle was followed by a final extension step at 72 C for 10 min. The PCR products were subjected to electrophoresis in 1.5 % (w/v) agarose gels. For DNA sequencing and restriction enzyme digestion, 100 ml PCR samples were fractionated by electrophoresis in 1.3 % (w/v) low-melting-point agarose gels. The separated bands were extracted from the gel slices by Qiagen PCR purification Kit (Qiagen, Venlo, Netherlands). Restriction enzyme digestion and sequencing of the PCR products were carried out as previously described [37, 40] . The following controls were used to check for possible amplification of contaminant DNA and RNA by PCR: RNA blanks taken throughout the cDNA synthesis step in the absence of reverse transcriptase; samples without templates were run for every primer pair for each PCR experiment; rat brain RNA was used as a positive control for each experiment; and, finally, primers for beta actin were used to test the viability of each cDNA sample.
Immunochemical analysis. MIN6 and COS-7 cells were washed three times with PBS then lysed in ice cold RIPA buffer (1 x PBS, 1.0 % (v/v) Nonidet P40, 0.5 % (w/v) sodium-deoxycholate and 0.1 % (w/v) SDS) containing protease inhibitors (1 mmol/l PMSF, 1 mmol/l iodoacetamide, 1 mmol/l benzamidine, 2 mmol/l DTT, 1 mmol/l EDTA, 0.1 mg/ml soybean trypsin inhibitor and 10 mmol/l leupeptin) and left on ice for 1 h. The cell lysate was centrifuged at 15 000´g max for 20 min at 4 C. Rat and human islets of Langerhans and rat brain samples were prepared as described above. The protein concentration of the supernatant was determined with BCA Protein Assay Kit (Pierce, Rockford, Ill., USA) using bovine serum albumin (BSA) as standard. Proteins were separated on 9 % (w/v) SDS polyacrylamide gels and transferred to Immobilon membranes (Millipore, Bedford, Mass., USA) using a discontinuous buffer system [39] . Blots were probed with 0.2±1 mg/ml immunoaffinity purified rabbit anti-mGluR2/3, anti-mGluR5 (Chemicon International, Temecula, Calif., USA), guinea pig GABA B R1 a/b and GABA B R2 (Oncogene Research Products, Cambridge, Mass., USA) antibodies. Following overnight incubation with the primary antibodies at 4 C, immunostaining was revealed with horseradish-peroxidase conjugated anti-rabbit IgG (1:40 000 dilution) using an enhanced chemiluminescence (ECL) detection system (Roche Diagnostics, Lewes, UK).
Assay of insulin secretion. MIN6 cells were plated at a density of 0.5´10 6 cells/well and cultured for 24 h. The cells were washed three times with PBS then incubated with HEPES-Krebs buffer (119 mmol/l NaCl, 4.75 mmol/l KCl, 5 mmol/l NaHCO 3 , 2.54 mmol/l CaCl 2 , 1.2 mmol/l MgSO 4 , 1.18 mmol/l KH 2 PO 4 and 20 mmol/l HEPES pH 7.4) containing 2 mg/ml BSA and 0.3 mmol/l glucose for 2 h at 37 C. This medium was replaced with fresh HEPES-Krebs buffer containing 2 mg/ml BSA and the test reagents. After a further 30 min incubation 100 ml medium was removed and added to 900 ml buffer containing 7.8 mmol/l NaH 2 PO 4 , 32.2 mmol/l Na 2 HPO 4 , 0.25 % (w/v) thiomersal and 0.1 % (w/v) BSA. Insulin secretion was measured either by radioimmunoassay [8] or by rat insulin ELISA Table 1 . Oligonucleotides used as PCR primers. The primers were based on rat or human (labelled with *) cDNA sequences. The EMBL/GenBank database accession numbers are indicated in the first column (Mercodia, Uppsala, Sweden). As described previously [41, 42] , the glucose-stimulated insulin secretion from MIN6-cells increased two-to four-fold when the glucose concentration was raised from 3 mmol/l to 25 mmol/l. For statistical analysis independent group t tests were used. A p < 0.05 (*) and p < 0.01 (**) were considered to be statistically significant with relevant control samples.
Results
Identification of mGluR isoforms in pancreatic islet cells using RT-PCR and immunoblotting. To determine whether mRNA encoding the mGluRs is present in pancreatic beta cells and rat and human islets of Langerhans, we designed isoform-specific primers (Table 1) for RT-PCR. We found that mRNAs for at least one of the mGluRs from each of the three groups could be detected in the majority of the clonal-islet cell lines and islets of Langerhans (Fig. 1) . From group I (mGluR1/5) [9] , mRNA for mGluR5, rat and human islets of Langerhans, a-TC, RINm5F and MIN6 cell lines could be detected in all samples. In contrast, mGluR1 mRNA was not found in any of the samples other than in the positive controls ( Fig. 1) . The group II (mGluR2/3) [9] receptor mGluR3 was also identified in all the samples examined, whereas very low amounts of mGluR2 were detected at very low levels in MIN6 cells only (Fig. 1) . The group III mGluRs (mGluR4/6±8) [9] show more limited expression patterns: mGluR4 was identified in rat islets of Langerhans but could not be detected in the cell lines or in human islets of Langerhans (Fig. 1) . The mGluR8 mRNA was detected in rat islets of Langerhans, RINm5F and MIN6 cells but not in a-TC or human islet cells (Fig. 1) . No mRNA could be detected for mGluR6 and mGluR7 in any of the samples tested but both isoforms were present in the positive controls (Fig. 1) . In order to confirm that the amplified PCR products correspond to the correct mGluR sequences we used restriction enzyme digestion or DNA sequencing (data not shown). All the above experiments were done in parallel with negative and positive controls using water or cDNAs from rat or human cerebral cortex or cerebellum as appropriate. The integrity of each cDNA sample was confirmed by the detection of beta-actin mRNA [40] (data not shown).
To confirm the expression of mGluR proteins, membrane fractions were prepared from rat and human islets of Langerhans and MIN6 cells. In immunoblots of both brain and islet cells, an immunoaffinity purified antibody against the common C-terminus sequence of rat mGluR2 and mGluR3 (Chemicon International) identified a dominant 100 kDa band. The molecular weight of this band corresponds well with the molecular weight of mGluR2/3 proteins identified in brain samples (Fig. 2, left panel) . Because the mGluR2 mRNA was not detected in human and rat islets (Fig. 1) , the identified protein probably corresponds to mGluR3. In rat brain mem- (Table 1) were used to detect mRNAs for each receptor subtype in human islets of Langerhans (HIL), rat islets of Langerhans (RIL), a-TC cells (a-TC), and RINm5F (RIN) and MIN6 beta cells (MIN). The positive and negative controls were rat brain mRNA (RB) and PCR reaction without template ((±) C) respectively. Primers for human mGluR5 amplified a different region than the rat mGluR5, hence the different sizes in the PCR product (see Table 1 for details). PCR products were verified by sequencing or by their restriction enzyme digestion patterns branes, in addition to the 100 kDa protein, the antimGluR2/3 antibody also identified a larger band (~190 kDa), which was thought to be a dimer of the smaller band [43] . An antibody against the C-terminal 13 amino acids of mGluR5 revealed a densely labelled band of 145 kDa in both human and rat islets of Langerhans, MIN6 and rat brain membrane fractions (Fig. 2, right panel) . After prolonged film exposure an additional weaker band of about~150±160 kDa was also visible. These apparent molecular weights are consistent with the predicted size of the glycosylated forms of mGluR5 isoforms and previous studies identified proteins with similar molecular weight in rat brain membranes using mGluR5 selective antibodies [43, 44] . Neither of the antibodies labelled COS-7 cell membrane fractions used as negative controls (not shown). Normal (pre-immune) rabbit and guinea pig sera produced negative results with all samples examined on immunoblots (not shown).
Effects of mGluR agonists on insulin secretion from MIN6 cells. To determine whether the mGluRs identified in the RT-PCR experiments and on immunoblots affect insulin secretion, we examined changes in insulin secretion from MIN6 cells in the presence of mGluR agonists at 3, 10 or 25 mmol/l glucose concentrations. The effect of the group I receptor specific agonist DHPG was studied at a concentration of 10 mmol/l (reported EC 50 2 mmol/l (mGluR5), 6.6 mmol/l (mGluR1) [9, 10] ). DHPG caused a significant (p < 0.01) increase in the release of insulin from MIN6 cells at lower glucose concentrations (3±10 mmol/l). However, it did not have any effect in the presence 25 mmol/l glucose (Fig. 3) . L-CCG-1 was used as the specific group II agonist, (reported EC 50 value for mGluR2 0.3±4 mmol/l and for mGluR3 1 mmol/l [9, 10] ). At 3±25 mmol/l glucose concentra- Fig. 2 . Detection of mGluR proteins in islets of Langerhans and MIN6 beta cells. Antibodies against mGluR2/3 and mGluR5 were used for immunoblotting of rat brain (RB), human (HIL) and rat islets of Langerhans (RIL), and MIN6 cell (MIN) membrane fractions. Immunoreactive bands with estimated molecular weights of 100 kDa and 145 kDa were observed after immunostaining with anti-mGluR2/3 and anti-GluR5 antibodies, respectively. In rat brain membrane samples, the anti-mGluR2/3 antibody also identified a larger band (~190 kDa), thought to be a dimer of the 100 kDa protein. None of the antibodies reacted with COS-7 cell membranes (not shown) For each experiment, a minimum of three parallel samples was used for each condition in three independent tests (n ³ 9). * Indicates p < 0.05; ** indicates p < 0.01 compared with control samples tions 3 mmol/l L-CCG-1 significantly (p < 0.01±0.05) increased the release of insulin from MIN6 cells, which was particularly prominent at 3 mmol/l glucose (Fig. 3) . The effect of L-CCG-1 required the presence of 3 mmol/l glucose because there was no noticeable increase at very low (0.3 mmol/l) glucose concentration (not shown). Group III receptors were examined using 3 mmol/l L-AP4, a specific agonist for this group with a reported EC 50 of between 0.4 and 1.2 mmol/l for mGluR4, 6 and 8 [9, 10] . The effect of L-AP4 was different at various glucose concentrations: At 3 mmol/l, glucose L-AP4 significantly (p < 0.01) increased the insulin release but at 10 mmol/l and 25 mmol/l glucose L-AP4 caused a significant (p < 0.05) inhibition compared to controls at the same glucose concentrations.
Identification of GABA B R isoforms in pancreatic islet cells using RT-PCR and immunoblotting.
The expression of mRNAs encoding for GABA B R1 and GA-BA B R2 isoforms was also examined. Primers designed to amplify GABA B R1a-b (Table 1 ) produced a single 525 bp product in MIN6 cells and human islets of Langerhans (Fig 4A) . This fragment could correspond to the a, b or d GABA B R1 splice variants [29] . In rat cerebellum, an additional (618 bp) PCR fragment was also amplified (Fig. 4A, CER ) which corresponds to GABA B R1c. The absence of this product in MIN6 cells and human islets of Langerhans suggests that GABA B R1c is not expressed in these samples (Fig. 4A) . This result was further confirmed by GA-BA B R1c specific primers (Table 1) , which did not produce a PCR product in either MIN6 cells or human islets of Langerhans but amplified a 671 bp band in brain (not shown). A GABA B R1d specific primer pair (Table 1) amplified a 509 bp fragment in both human (Fig. 4A) and rat (not shown) islets of Langerhans but not in MIN6 cells (Fig. 4A) . GABA B R2 specific primers (Table 1 ) amplified a single 357 bp product in all samples tested (Fig. 4A ). Taking these data together, beta cells express GABA B R1a or GABA B R1b or both together with GABA B R2, while GABA B R1d is probably expressed in an other islet cell types. Neither GABA B R subtype mRNA could be detected in the acell line, a-TC9 cells (not shown).
Immunoblotting of MIN6 cells, human islets of Langerhans and cerebellar membranes with an anti- [23] . The GA-BA B R2 selective immunoaffinity purified antibody (Chemicon International) revealed a single band of 110 kDa, which is consistent with the predicted size of GABA B R2 and with the observed molecular weights in brain homogenates [23] (Fig. 4C) .
The effect of GABA B R selective agonist baclofen on insulin secretion. To examine the effects of GABA B R stimulation in MIN6 cells, we used the specific agonist baclofen (10 mmol/l [45] ) in conjunction with either 3, 10 or 25 mmol/l glucose. We found that at the lower concentrations of glucose (3 and 10 mmol/l) there was no noticeable difference in the amount of insulin released from MIN6 cells in the presence or absence of baclofen. However at 25 mmol/l glucose, baclofen significantly (p < 0.01) inhibited the release of insulin by~34 % compared to controls at the same glucose concentration (Fig. 4C) .
Discussion
Functional metabotropic glutamate and GABA receptors are expressed in the endocrine pancreas and their effects on insulin secretion is glucose concentration dependent. The data described here indicate that pancreatic islet cells express mGluRs and GABA B Rs identical with receptors expressed in the CNS [9, 10, 29] . We found mRNAs for the mGluR3 and mGluR5 in all the cell types examined (rat and human islets of Langerhans and MIN6, RINm5F, a-TC clonal cell lines). A trace amount of mGluR2 was found in MIN6 cells but not in any other cell types. mGluR4 was identified in rat islets only. The expression of mGluR8 was detected in rat islets, RINm5F and MIN6 cells. The variations in the expression patterns of mGluR2 could be due to differences in species, cell types or altered gene expression in transformed cell lines compared to the host cells. Additionally, mGluR4 could be expressed in rat d cells but not in a or beta cells, hence the absence of mGluR4 mRNA in a-and beta-cell lines. mRNAs encoding mGluR1, mGluR6 and mGluR7 were not found in [67] are described elsewhere any of the cell types examined. This is consistent with a previous study [19] , where neurones and MIN6 cells were used to study AMPA receptor-mediated regulation of G i -proteins. RT-PCR analysis with mGluR6 specific primers and immunoblots indicated that mGluR6 is not expressed in MIN6 cells [19] . These authors have not reported the expression of the other mGluR isoforms identified in our study [19] . However, some caution is needed in interpretation of the results regarding the presence of mRNAs in a cell line because this does not necessarily indicate the presence of functional receptors [15, 46] . Therefore, it is important to investigate whether the mGluR mRNAs found in beta cells are actually translated into proteins. In this study, we confirmed the expression of mGluR3 and mGluR5 proteins using selective antibodies (Fig. 2) .
In the CNS glutamate concentration decreases sharply away from the release site [47] . Therefore, it is interesting to note that the mGluRs shown to be present in beta cells, are those that have the highest affinity for the endogenous ligand, glutamate [9, 10] . The expression of these high affinity mGluR isoforms could be due to the cellular organisation of islets [48] , where these receptors are exposed to lower glutamate concentrations compared with neuronal synapses.
We used the MIN6 beta-cell line to study the functional role of the identified mGluR proteins using group I (mGluR1/5), group II (mGluR2/3) and group III (mGluR4/6±8) specific agonists DHPG, L-CCG-1 and L-AP4 respectively [9, 10] . We studied the effects of these agonists on secretion of insulin at various glucose concentrations (3, 10 and 25 mmol/l). The group II agonist L-CCG-1 caused a~1.8-fold higher increase in insulin secretion than in controls in the presence of 3 mmol/l glucose; there was relatively smaller L-CCG-1-induced increase in insulin secretion at higher glucose concentrations (Fig. 3) . These results indicate that mGluR3 can improve the release of insulin in the presence of glucose. The concentration of glucose required for the potentiating effects of L-CCG-1 in MIN6 cells is low (3 mmol/l). DHPG, the group I agonist [9, 10] , stimulated the release of insulin from MIN6 cells at 3 and 10 mmol/l glucose. Interestingly, this stimulation by DHPG was abolished by high concentrations of glucose (Fig. 3) . L-AP4, a group III agonist [9, 10] , produced moderate activation at 3 mmol/l glucose and caused an inhibition at high glucose concentrations (10±25 mmol/l). These results indicate the functional presence of at least one member of each mGluR group in MIN6 cells and that each group has a different effect on insulin secretion. In the case of the group I receptors this is likely to be mGluR5 as mGluR1 mRNA could not be detected in MIN6 cells (Fig. 1) . The identified mGluR3 is an L-CCG-1 sensitive group II receptor. Of the group III receptors, mGluR8 is the only mGluR detected in MIN6 cells from this group (Fig. 1) and is probably mediating the L-AP4-stimulated effect on insulin secretion (Fig. 3) .
GABA B R1 and GABA B R2 mRNAs were identified in human and rat islets and MIN6 cells (Fig. 4A) . Their expression was confirmed by immunoblot analysis (Fig. 4B) . Splice variant specific primers revealed that GABA B R1a and GABA B R1b are present in beta cells, whereas GABA B R1 d is only present in islets but not in the MIN6 beta-cell line. This suggests that GABA B R1d is probably found in pancreatic polypeptide cells or d-cells or both. Neither GABA B R subtype mRNA could be detected in the a-cell line, a-TC9 cells, indicating that GABA B Rs are not present in a cells. The observed distribution of the GABA B R is in contrast to the distribution of the GABA A Rs, which are located on a cells [1, 3] . Recent evidence has shown that GABA B Rs must exist as a heterodimer to form a functional receptor at the plasma membrane [22, 24±26, 29] . The presence of both isoforms in beta cells suggests that they can assemble to functional GABA B Rs heterodimers. We showed that in the presence of 25 mmol/l glucose the GABA B R agonist, baclofen [45] , inhibited the secretion of insulin from MIN6 cells, thus showing that a functional GABA B R is expressed in this cell line (Fig. 4C) .
Different transduction pathways could be involved in the glutamate and GABA mediated modulation of insulin secretion. The metabolism of glucose leads to the formation of ATP in beta-cells (Fig. 5) (Fig. 5 ) [48] . The increased intracellular [Ca 2+ ] i stimulates the release of insulin and GABA from beta cells (Fig. 5) [1, 3, 48] . Glutamate, which could be released from a cells, autonomic nerve fibres or the dietary glutamate, could affect insulin secretion [1, 6, 7, 13] . There are glutamatergic neurones and glutamate-mediated neurotransmission in the enteric nervous system [49] ; therefore glutamate could be released from autonomic nerve fibres terminating within the pancreatic islet. It has been suggested that glutamate is also released from mitochondria and acts as a messenger in beta cells in glucose-induced insulin exocytosis [50] . However, new studies raised doubts on the proposed intracellular messenger role of glutamate in glucose-induced insulin secretion [51, 52] .
In our study, the selective activation of each mGluR group produced a characteristic effect on insulin secretion (Fig. 3) . This is probably a reflection of the different transduction pathways that couple to these receptors [9] (Fig. 5) . Group I receptors (Fig. 5,  mGluR5 ) can potentiate the release of Ca 2+ from intracellular stores by activation of phospholipase C (PLC) [10] which in turn could lead to the release of insulin (Fig. 5) as observed with the agonist DHPG (Fig. 3) . Indeed, stimulation of mGluR5 in MIN6 cells with DHPG caused a considerable reduction in the endoplasmic reticulum (ER) Ca 2+ concentration monitored by ER-targeted aequorin [53] and an increase in intracellular [Ca 2+ ] i using fura-2 (Varadi A., unpublished data). In neurones group I mGluR agonists inhibit K ATP channels by selective actions of the mGluR1/5 activated Ga subunits [54] . This provides an additional mechanism for the stimulation of insulin release observed after the activation of mGluR5 by DHPG (Fig. 3) . Group III receptors (Fig. 5, mGluR8 ) inhibit adenylyl cyclase (AC) by the G-protein G i [9] . This pathway has been shown to enhance K ATP channel activity and to inhibit L-type VDCCs [55, 56] , which would inhibit the release of insulin as observed following the activation of mGluR8 using L-AP4 at 10 and 25 mmol/l glucose (Fig 3 and 5) . In neurones, group II mGluRs are usually linked to the inhibition of cAMP formation but there are examples of group II mGluR agonists potentiating cAMP responses in some cells [9, 11] , which would explain the stimulatory effects of L-CCG-1 on beta-cell insulin secretion ( Fig. 3 and 5 ). Glutamate can also modulate insulin secretion via iGluRs by increasing their Na + , K + and possibly Ca 2+ conductance [1, 6, 7] (Fig. 5 ). It is known that beta cells can produce and release GABA in response to glucose [1, 2, 4] (Fig. 5) . It has been suggested that the released GABA hyperpolarizes a-cells through GABA A Rs [3] and inhibits the release of glucagon in the presence of high glucose [57] (Fig. 5) . However, our present study also shows a GA-BA B R mediated inhibition of insulin release in the presence of high glucose concentrations. GABA B R stimulates the G-protein G o , which is known to inhibit N-, P-and R-type VDCCs [58, 59] all of which are expressed in pancreatic beta cells [60±62] . This suggests that GABA B Rs could act as a negative feedback mechanism, possibly through G-protein inhibition of VDCC to prevent dangerously high concentrations of Ca 2+ entering the cell in hyperglycaemic conditions (Fig. 5) . In neurones, K ATP channels are activated by a GABA B R agonist [54, 63] , which could also contribute to the GABA B R mediated inhibition of insulin secretion (Fig. 4C, 5) . Interestingly, treatment of nonobese diabetic mice with the GABA B R agonist baclofen [45] delayed the onset of diabetes [35] .
This work clearly shows the presence of functional mGluRs and GABA B Rs in pancreatic endocrine cells and their ability to modulate secretion of insulin from beta cells. The presence of these receptors in the endocrine pancreas should be also considered during the development of new mGluR and GABA B R specific pharmacological agents for novel treatment strategies of psychiatric and neurological disorders to avoid potential side effects.
